Procurement and supply management activities are fundamental to consistent and reliable access to essential medicines and health products. To reduce the impact of CVD, action needs to be taken to improve prevention, diagnosis, care and management of CVD diseases. Affordable essential medicines and t...echnologies to manage CVD disease must be available where and when they are required. Medicines and technologies need to be managed appropriately to ensure that the correct medicines are selected, procured in the right quantities, distributed to facilities in a timely manner, and handled and stored in a way that maintains their quality. This needs to be backed up by policies that enable sufficient quantities to be procured in order to reduce cost inefficiencies, ensure the reliability and security of the distribution system, and encourage the appropriate use of these health products. In order to avoid stock-outs and the disruption of treatment, all related activities need to be conducted in a timely manner, with performance continually monitored, and prompt action taken in response to problems that may arise. Additionally, medication must be dispensed correctly and used rationally by the healthcare provider and patient alike. The purpose of this guide is to explain the necessary steps.
more
L’utilisation excessive ou inadaptée des antibiotiques chez l’homme et chez l’animal contribue à amplifier la menace provenant de la résistance à ces produits. Certains types de bactéries susceptibles de provoquer des infections graves chez les humains sont déjà devenus ... résistants à la plupart des traitements disponibles et très peu d’options prometteuses sont actuellement en cours de développement pour prendre le relais
more
En mai 2015, en adoptant le Plan d’action mondial pour combattre la résistance aux antimicrobiens (« Plan d’action mondial »), la Soixante-Huitième Assemblée mondiale de la Santé a reconnu l’importance de cette résistance en tant que problème majeur de santé publi...que. Le Plan propose des interventions pour lutter contre cette résistance, dont la réduction des usages inutiles d’antimicrobiens chez l’homme et chez l’animal. Il souligne aussi la nécessité d’une approche intersectorielle, « Un monde, une santé », pour endiguer cette résistance, impliquant des efforts de la part d’acteurs de nombreuses disciplines, dont les médecines humaine et vétérinaire
more
Afr J Tradit Complement Altern Med. (2013) 10(5):210-229
Plants are important sources of medicines. Herbal medicines in Lesotho are exposed to excessive exploitation and habitat destruction. Comprehensive information to promote proper use and conservation of these herbal medicines is lacking. ...This study described the uses of medicinal plants in Lesotho with comparative reference between practice and the literature, highlighting important ethno-medicinal information and conservation status of the plants. Additionally, the study established a repository and monograph for the herbal medicines in Lesotho.
http://dx.doi.org/10.4314/ajtcam.v13i1.20
more
760 WEEKLY EPIDEMIOLOGICAL RECORD, NOS. 51/52, 20 DECEMBER 2024, pp.760-769. In French and English
EClinicalMedicine 1 (2018) 21–27
https://doi.org/10.1016/j.eclinm.2018.06.005
2589-5370/© 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
EClinicalMedicine: journal homepage: https://www.jo...urnals.elsevier.com/ eclinicalmedicine
Research Paper
more
REG 174 INFORMATION FOR UK HEALTHCARE PROFESSIONALS
The Indigenous tribe called the Wiwa lives retracted in the Sierra Nevada de Santa Marta, Colombia. Little is known about their health status and whether the health care system in place covers their needs.
BMC Medicine201210:107
https://doi.org/10.1186/1741-7015-10-107© Katchanov and Birbeck; licensee BioMed Central Ltd. 2012
Received: 10 July 2012Accepted: 24 September 2012Published: 24 September 2012
In 2011, the World Health Organization’s (WHO) mental health Gap Action Programme (mhGAP) r...eleased evidence-based epilepsy-care guidelines for use in low and middle income countries (LAMICs). From a
geographical, sociocultural, and political perspective, LAMICs represent a heterogenous group with significant differences in the epidemiology, etiology, and perceptions of epilepsy. Successful implementation of
the guidelines requires local adaptation for use within individual countries. For effective implementation and sustainability, the sense of ownership and empowerment must be transferred from the global health authorities to the local people. Sociocultural and financial barriers that impede the implementation of the guidelines should be
identified and ameliorated. Impact assessment and program revisions should be planned and a budget allocated to them. If effectively implemented, as intended, at the primary-care level, the mhGAP
guidelines have the potential to facilitate a substantial reduction in the epilepsy treatment gap and improve the quality of epilepsy care in resource-limited settings.
more
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
More than 40% of the world population is 24 years old or younger, the vast majority of whom live in low- and lower middle–income countries. Globally, a quarter of disability-adjusted life years (DALYs) for mental disorders and substance abuse is borne by this age group and about 75% of mental diso...rders diagnosed in adulthood have their onset before the age of
24 years . Most children and young people in developing countries, however, do not have access to mental health care.
more
Anema et al. AIDS Research and Therapy 2011, 8:13 http://www.aidsrestherapy.com/content/8/1/13